Hansoh Pharmaceutical Group Company Limited: Carcinoma, Non-Small-Cell Lung trials

The registry lists 25 Carcinoma, Non-Small-Cell Lung studies with Hansoh Pharmaceutical Group Company Limited as lead sponsor. 19 are open to participants now and 2 have results posted.

Phase 1 13Phase 2 6Phase 3 10(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Phase II Study of HS-20093 Injection Combined With Adebrelimab Versus HS-20093 Injection in Previously Treated Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Without Actionable Genomic AlterationsRecruitingNCT07824882Phase 2
• A Study Evaluating HS-10370 Plus Platinum-based Doublet Chemotherapy With or Without Adebrelimab vs. Tislelizumab Plus Chemotherapy as First-Line Therapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung CancerNot yet recruitingNCT07822542Phase 3
• Phase III Study of HS-10504 Versus Platinum-Based Doublet Chemotherapy in Patients With C797S+ NSCLCNot yet recruitingNCT07754123Phase 3
• A Phase III Study of HS-20093 Injection Combined With Adebrelimab Versus Docetaxel in Previously Treated Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Without Actionable Genomic AlterationsNot yet recruitingNCT07464327Phase 3
• A Study of Aumolertinib in European Participants With Non-Small Cell Lung CancerRecruitingNCT07130916Phase 1
• A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Patients With Advanced Solid TumorsNot yet recruitingNCT06963502Phase 1
• A Study Evaluating the Effect of Aumolertinib on the Pharmacokinetics of Midazolam in Patients With NSCLCRecruitingNCT06926413Phase 1
• Pharmacokinetic Study of HS-10365 Capsule in Subjects with Hepatic Impairment and Normal Hepatic FunctionNot yet recruitingNCT06823258Phase 1
• Pharmacokinetic Study of HS-10241 Tablets in Subjects with Hepatic Impairment and Normal Hepatic FunctionNot yet recruitingNCT06823245Phase 1
• Phase Ib Trial of HS-20117 in Combination With Other Drugs in Advanced Solid TumorsRecruitingNCT06621563Phase 1
• A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Participants with KRAS G12C Mutation Advanced Solid TumorsNot yet recruitingNCT06594874Phase 1
• A Study of HS-10504 in Patients With Advanced or Metastatic Non-Small-Cell Lung Cancer(NSCLC)RecruitingNCT06461156Phase 1
• A Study of HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung CancerRecruitingNCT06417008Phase 2/3
• A Study of HS-10365 in Patients With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung CancerRecruitingNCT06147570Phase 2
• A Study of HS-10241 Combined With Almonertinib Versus Platinum-based Chemotherapy in Treatment of Advanced NSCLC With MET Amplification After Failure of EGFR-TKI TherapyNot yet recruitingNCT06110663Phase 3
• A Phase I Clinical Study of HS-20117 in Participants With Advanced Solid TumorsNot yet recruitingNCT05940116Phase 1
• Phase 1/2 Study of HS-10376 in Patients With Non-Small Cell Lung CancerRecruitingNCT05435274Phase 1/2
• Phase 1/2 Study of HS-10375 in Patients with Advanced or Metastatic Non-Small-Cell Lung Cancer(NSCLC)RecruitingNCT05435248Phase 1/2
• A Phase III Study to Assess the Effects of Almonertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung CancerRecruitingNCT04951635Phase 3
• A Study to Evaluate Safety and Efficacy of HS-10296 as First-Line Treatment in PatientsStatus unknownNCT03849768Phase 3Results posted
• A Study to Evaluate Safety, PK and Efficacy of HS-10296 in Patients With NSCLCStatus unknownNCT02981108Phase 1/2Results posted
• Study of HS-10241 in Combination With Almonertinib in Patients With Locally Advanced or Metastatic NSCLCStatus unknownNCT05430386Phase 1
• A Phase III Study to Assess the Efficacy and Safety of Almonertinib Versus Platinum-based Chemotherapy as First-line Therapy in Patients With Locally Advanced or Metastatic NSCLC Harbouring Uncommon EGFR MutationStatus unknownNCT04951648Phase 3
• Aumolertinib with or Without Chemotherapy As 1st Line Treatment in Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Sensitizing EGFR MutationsActive, not recruitingNCT04923906Phase 3
• Almonertinib Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB Non-Small Cell Lung Cancer With EGFR-sensitive MutationsActive, not recruitingNCT04687241Phase 3